| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to pharmaceutical application of selective negative allosteric modulators GABA A ?5 for treatment, prevention and/or retardation of development of central nervous system condition, related to excessive GABA-ergic inhibition in brain. Claimed are: application of negative allosteric modulator GABA A ?5, (1,1-dioxo-1,6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone or its pharmaceutically acceptable salt for treatment, prevention and/or retardation of development of said CNS conditions, selected from cognitive disorders in case of Down's syndrome, autism, type I neurofibromatosis or after stroke (versions) and pharmaceutical composition for said purpose.EFFECT: compound reverses deficiency of long-time neuron potentiation, restores neuron proliferation and density of granular cells in hippocampus, and recovers impaired spatial learning.13 cl, 23 dwg, 5 tbl |
